This novel finding is in line with reports that the development of blood eosinophilia upon treatment with immunotherapy drugs, such as checkpoint inhibitors anti-CTLA-4 and anti-PD-1, is a predictor of the clinical response. Here, CTLA4 is linked to Increased total eosinophil count.